<DOC>
	<DOCNO>NCT00962377</DOCNO>
	<brief_summary>This study design evaluate safety efficacy peripheral blood mononuclear cell gene expression profile method ( AlloMap ) monitoring asymptomatic heart transplant patient acute rejection begin 2-6 month ( ≥ 55-185 day ) transplantation .</brief_summary>
	<brief_title>A Comparison AlloMap Molecular Testing Traditional Biopsy-based Surveillance Heart Transplant Rejection Early Post-transplantation</brief_title>
	<detailed_description>Cardiac allograft rejection experience 20-50 % patient least first year cardiac transplantation present immunosuppression regimen . The standard rejection surveillance endomyocardial biopsy ( EMB ) . However , EMB invasive , cause morbidity , subject sample error inter-observer variability . Gene expression profile ( GEP ) , high negative predictive value ( NPV ) acute cellular rejection ( ACR ) , appear well suit identify low-risk patient safely manage without routine invasive endomyocardial biopsy ( EMB ) . The Invasive Monitoring Attenuation Gene Expression ( IMAGE ) multicenter study conduct year 2005-2009 study patient &gt; 6 months-5 year post transplant . The IMAGE study demonstrate clinical outcome heart transplant patient manage AlloMap® noninferior patient manage EMB . The EIMAGE study expand time window study include patient 2 month ( ≥ 55 day ) post-transplant . This early time frame study primary difference EIMAGE study IMAGE study .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<criteria>1 . Heart transplant recipient 26 month ( ≥55 day 185 day ) posttransplant time first study surveillance visit 2 . Age ≥ 18 year 3 . Left ventricular ejection fraction ≥ 50 % Echocardiography , Multiple Gated Acquisition ( MUGA ) scan , ventriculography study entry ( baseline / enrollment study ) 1 . Any clinical sign decline graft function : Symptoms Congestive Heart Failure ( CHF ) first study surveillance visit Signs decompensated heart failure , include development new S3 gallop enrollment visit Elevated right heart pressure diminish cardiac index &lt; 2.2 L/min/m2 new compare previous measurement within 2 month Decrease LVEF measure echocardiography : ≥ 25 % compare prior measurement within 2 month 2 . Rejection therapy biopsyproven ISHLT Grade 3A high precede 2 month 3 . Prior current evidence antibodymediated rejection ( AMR ) . AMR define accord ISHLT 2004 Guidelines positive histology immunopathology ( either immunofluorescence immunoperoxidase ) stain AMR 4 . Major change immunosuppression therapy within previous 30 day ( e.g. , discontinuation calcineurin inhibitor , switch mycophenolate mofetil sirolimus vice versa ) 5 . Unable give write informed consent 6 . Patient receive hematopoietic growth factor ( e.g. , Neupogen , Epogen ) currently previous 30 day 7 . Patients receive ≥ 20 mg/day prednisone equivalent corticosteroid time first study surveillance visit 8 . Patient enrol trial require routine surveillance endomyocardial biopsy 9 . Patient receive transfusion within precede 4 week 10 . Patients endstage renal disease require form renal replacement therapy ( hemodialysis peritoneal dialysis ) 11 . Pregnancy time first study surveillance visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>molecular expression test</keyword>
	<keyword>right ventricular endomyocardial biopsy</keyword>
</DOC>